{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:12:58Z","timestamp":1768871578903,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"DOI":"10.7759\/cureus.101836","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:51:14Z","timestamp":1768827074000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of Patients With Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4\/6 (CDK4\/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center"],"prefix":"10.7759","author":[{"given":"Alfredo Sebastian","family":"Golemba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mand\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Lucia","family":"Jimenez Bola\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirly Patricia","family":"Rodr\u00edguez Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rusvelt","family":"Vargas Moranth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astor Alfonso","family":"Aguirre Santamaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000232","article-title":"Molecular classification of breast cancer","volume":"27","author":"Tsang JY","year":"2020","unstructured":"Tsang JY, Tse GM. Molecular classification of breast cancer. Adv Anat Pathol. 2020, 27:27-35. 10.1097\/PAP.0000000000000232","journal-title":"Adv Anat Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader N","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014, 106:dju055. 10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015)","volume":"39","author":"Cardoso F","year":"2018","unstructured":"Cardoso F, Spence D, Mertz S, et al.. Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015). Breast. 2018, 39:131-8. 10.1016\/j.breast.2018.03.002","journal-title":"Breast"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl S","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al.. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024, 35:159-82. 10.1016\/j.annonc.2023.11.016","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01745-8","article-title":"Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials","volume":"404","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2024","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet. 2024, 404:1407-18. 10.1016\/S0140-6736(24)01745-8","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab202.","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"8","author":"Pedersen RN","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, et al.. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. J Natl Cancer Inst. 2022, 8:391-399. 10.1093\/jnci\/djab202.","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.541","article-title":"Short-term risk of recurrence in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): a meta-analysis","volume":"42","author":"Curigliano G","year":"2024","unstructured":"Curigliano G, Ciruelos E, Kalinsky K, et al.. Short-term risk of recurrence in patients (pts) with HR+\/HER2\u2212 early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): a meta-analysis. J Clin Oncol. 2024, 42:541. 10.1200\/JCO.2024.42.16_suppl.541","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104437","article-title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2- early breast cancer","volume":"81","author":"O'Shaughnessy J","year":"2025","unstructured":"O'Shaughnessy J, Tolaney SM, Yardley DA, et al.. Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+\/HER2- early breast cancer. Breast. 2025, 81:104437. 10.1016\/j.breast.2025.104437","journal-title":"Breast"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon DJ","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, et al.. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024, 42:994-1000. 10.1200\/JCO.23.00137","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz MP","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, et al.. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024, 35:718-27. 10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi GN","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al.. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022, 386:942-50. 10.1056\/NEJMoa2114663","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.010","article-title":"Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+\/HER2- breast cancer and residual disease after neoadjuvant chemotherapy","volume":"36","author":"Loibl S","year":"2025","unstructured":"Loibl S, Martin M, Bonnefoi H, et al.. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+\/HER2- breast cancer and residual disease after neoadjuvant chemotherapy. Ann Oncol. 2025, 36:832-7. 10.1016\/j.annonc.2025.03.010","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02554","article-title":"Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/aft-05\/Big-14-03)","volume":"40","author":"Gnant M","year":"2022","unstructured":"Gnant M, Dueck AC, Frantal S, et al.. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42\/aft-05\/Big-14-03). J Clin Oncol. 2022, 40:282-93. 10.1200\/JCO.21.02554","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston SR","year":"2020","unstructured":"Johnston SR, Harbeck N, Hegg R, et al.. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020, 38:3987-98. 10.1200\/JCO.20.02514","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon D","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al.. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024, 390:1080-91. 10.1056\/NEJMoa2305488","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00726-x","article-title":"Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and\/or ribociclib","volume":"11","author":"Ladoire S","year":"2025","unstructured":"Ladoire S, Kamga AM, Galland L, et al.. Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and\/or ribociclib. NPJ Breast Cancer. 2025, 11:10. 10.1038\/s41523-025-00726-x","journal-title":"NPJ Breast Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105304","article-title":"Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+\/HER2- early breast cancer: a United States Electronic Health Records database analysis","volume":"10","author":"Tarantino P","year":"2025","unstructured":"Tarantino P, Rugo HS, Curigliano G, et al.. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+\/HER2- early breast cancer: a United States Electronic Health Records database analysis. ESMO Open. 2025, 10:105304. 10.1016\/j.esmoop.2025.105304","journal-title":"ESMO Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.08.022","article-title":"Real-world analysis of breast cancer patients qualifying for adjuvant CDK4\/6 inhibitors","volume":"25","author":"Kanjanapan Y","year":"2025","unstructured":"Kanjanapan Y, Anderson W, Smith M, Green J, Chalker E, Craft P. Real-world analysis of breast cancer patients qualifying for adjuvant CDK4\/6 inhibitors. Clin Breast Cancer. 2025, 25:e159-69.e2. 10.1016\/j.clbc.2024.08.022","journal-title":"Clin Breast Cancer"},{"key":"ref20","article-title":"Incidence and clinicopathological characteristics of premenopausal patients with early luminal breast cancer candidates for adjuvant therapy with abemaciclib (Article in Spanish)","volume":"28","author":"Lopez V","year":"2023","unstructured":"Lopez V, Nico A, Jove F, Aguilar A, C\u00e1ceres V. Incidence and clinicopathological characteristics of premenopausal patients with early luminal breast cancer candidates for adjuvant therapy with abemaciclib (Article in Spanish). Oncol Clin. 2023, 28:","journal-title":"Oncol Clin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P1-11-23","article-title":"Abstract P1-11-23: risk of disease recurrence among patients with stage II and III HR-positive, HER2-negative breast cancer in Colombia: a retrospective cohort study","volume":"31","author":"Jhon Bola\u00f1os MC","year":"2025","unstructured":"Jhon Bola\u00f1os MC, Bello C, Benavides C. Abstract P1-11-23: risk of disease recurrence among patients with stage II and III HR-positive, HER2-negative breast cancer in Colombia: a retrospective cohort study. Clin Cancer Res. 2025, 31:1-11. 10.1158\/1557-3265.SABCS24-P1-11-23","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/411651-characteristics-of-patients-with-hormone-receptor-positivehuman-epidermal-growth-factor-receptor-2-negative-early-breast-cancer-eligible-for-adjuvant-cyclin-dependent-kinase-46-cdk46-inhibitors-real-life-evidence-in-a-colombian-cancer-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:51:15Z","timestamp":1768827075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/411651-characteristics-of-patients-with-hormone-receptor-positivehuman-epidermal-growth-factor-receptor-2-negative-early-breast-cancer-eligible-for-adjuvant-cyclin-dependent-kinase-46-cdk46-inhibitors-real-life-evidence-in-a-colombian-cancer-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.101836","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}